A leader in neuroscience, with a track record of successful management and leadership of large multidisciplinary groups of in vitro and in vivo scientists within big pharma and biotechnology companies. Responsible for the scientific direction, integrity of the work, timely delivery of objectives and development of the team. Responsibility to identify, monitor, interpret and present studies run in-house or by CROs in a variety of different therapeutic areas. Able to motivate staff to achieve high standards. Member of senior leadership teams, providing expert strategic input into all programme teams across all stages of the portfolio. With a proven track record of achievements as a project leader and extensive scientific background as a neuroscientist with more than 50 publications. Focused and reliable with excellent people skills, managing the business needs and delivering results through the leadership of large teams within the function or in the matrix, ensuring scientific excellence. Current position: Director, Drug Discovery and Development Consultants, Cambridge, UK. June 18-present Consultant with expertise in in vitro and in vivo biology, responsible for providing expert advice and support across all aspects of the small molecule drug discovery and development process. Previous positions: Head of Biology, Proximagen Ltd, London and Cambridge, UK. Feb 09-June 18 Management and leadership of a multidisciplinary group of up to 13 in vitro and in vivo scientists, focusing on neurodegeneration, pain, inflammation and other opportunistic therapeutic areas including fibrosis and IBD. Provided in vivo PK support for all projects. Senior Team Leader, Neurodegeneration, GlaxoSmithKline, Harlow, UK. Feb 02-Apr 08. Management and leadership of groups of up to 13 scientists, working on models for Alzheimer's disease (AD), multiple sclerosis (MS), Parkinson’s disease (PD) and stroke. Laboratory Head, Pharmacology, Novartis Institute for Medical Sciences (NIMS), London, UK. May 01-Feb 02. Responsible for the characterisation of new analgesic compounds and the management of four scientists. Senior Group Leader, Pfizer Global Res. and Dev., Cambridge, UK. Dec 00-May 01. Management of four scientists for the establishment of models of sexual behaviour to evaluate novel mechanisms for the treatment of sexual dysfunction. Group Leader, Senior Research Associate and Post-doctoral Fellow at Dept. Behavioural Pharmacology, Parke-Davis Neurosci. Res. Centre, Cambridge, UK. March 97-Dec 00. Management of four scientists and responsible for design of studies to assess novel compounds for different research projects, involving pain, anxiety, epilepsy, combination therapy, drug consumption and tolerance. Post-doctoral Research Fellow, Dept. Obstetrics and Gynaecology, St. George’s Hospital Medical School, London, UK. Funded by Wellcome Trust and Individual Fellowship, Human Capital and Mobility Program, EEC. Jan 94-March 97. Investigation of the interaction between neonatal 5HT and testosterone on the development of sexually dimorphic behaviours, as well as the role of α-melanocyte stimulating hormone, melanin-concentrating hormone and Neuropeptide E-I on cerebral functions in the rat. Lecturer in Animal Physiology (Profesor Ayudante de Escuela Universitaria), Physiology Dept., Faculty of Biology, Universidad Complutense, Madrid, Spain. 1992-Jan 94. Presented Neurophysiology lectures and practical classes to final year and PhD. students. Responsible for running Animal Physiology practical classes for final year students. Research Fellow. Physiology Dept., Universidad Complutense, Madrid, Spain. Personal grant, Ministerio de Educacion y Ciencia, Spain. 1988-1991. Focused on the interaction of neonatal monoamines and steroids on sexual dimorphism of steroid secretion and brain amine levels in adulthood (measured by HPLC-electrochemical detection). Research Pharmacologist. JUSTE S.A.Q.F. (Chem-Pharm Co., Madrid, Spain). 1987-1988. Carried out several behavioural and neurochemical studies on the development of analgesic drugs structurally related to serotonin.